Gastrointestinal Stromal Tumors Therapeutics Market 2027 By Route Of Administration, Distribution Channel and Geography | The Insight Partners

Gastrointestinal Stromal Tumors Therapeutics Market to 2027 - Global Analysis and Forecasts by Route Of Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00005556 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Gastrointestinal stromal tumor is the most common mesenchymal tumors in the world. Benign form of gastrointestinal stromal tumors may occur in all parts of gastrointestinal tract. In many cases it spreads in other parts of body which create further critical conditions. Due to this the research is now focused on gene therapy which could stop and reoccurrence of tumor.

MARKET DYNAMICS
The gastrointestinal stromal tumors therapeutics market is expected to grow exponentially in the forecast period owing to the factors such as increased investment in R&D of this segment and chances of reoccurrence of tumor even after surgical removal. Furthermore, the gene therapy and advent of regenerative therapy is anticipated to offer significant growth opportunities in the market during the forecast period.

MARKET SCOPE
The "Global Gastrointestinal Stromal Tumors Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a particular focus on the global market trend analysis. The report aims to provide an overview of the gastrointestinal stromal tumors therapeutics market with detailed market segmentation by route of administration, distribution channel and geography. The global gastrointestinal stromal tumors therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading gastrointestinal stromal tumors therapeutics market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global gastrointestinal stromal tumors therapeutics market is segmented on the basis of administration and distribution channel. Based on rote of administration, the market is bifurcated into oral and parenteral. Based on distribution channel the market is classified as hospital pharmacies, retail pharmacies and online pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global gastrointestinal stromal tumors therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The gastrointestinal stromal tumors therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting gastrointestinal stromal tumors therapeutics market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the gastrointestinal stromal tumors therapeutics market in these regions.

MARKET PLAYERS
The reports cover key developments in the gastrointestinal stromal tumors therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from gastrointestinal stromal tumors therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for gastrointestinal stromal tumors therapeutics market in the global market. Below mentioned is the list of few companies engaged in the gastrointestinal stromal tumors therapeutics market.

The report also includes the profiles of key gastrointestinal stromal tumors therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • AROG Pharmaceuticals, INC.
  • Bayer AG
  • Boston Biomedical
  • Celldex Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Immunicum AB.
  • NATCO Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gastrointestinal Stromal Tumors Therapeutics Market - By Route Of Administration
1.3.2 Gastrointestinal Stromal Tumors Therapeutics Market - By Distribution Channel
1.3.3 Gastrointestinal Stromal Tumors Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
7.1. OVERVIEW
7.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
7.3. ORAL
7.3.1. Overview
7.3.2. Oral Market Forecast and Analysis
7.4. PARENTERAL
7.4.1. Overview
7.4.2. Parenteral Market Forecast and Analysis
8. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.1.2 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.1.3 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.1.4 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.1.1 United States Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.1.2 United States Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.1.5.2 Canada Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.2.1 Canada Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.2.2 Canada Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.1.5.3 Mexico Gastrointestinal Stromal Tumors Therapeutics Market
9.1.5.3.1 Mexico Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.1.5.3.2 Mexico Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.2.2 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.2.3 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.2.4 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.1.1 Germany Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.1.2 Germany Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.2 France Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.2.1 France Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.2.2 France Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.3 Italy Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.3.1 Italy Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.3.2 Italy Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.4 Spain Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.4.1 Spain Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.4.2 Spain Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.2.5.5 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market
9.2.5.5.1 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.2.5.5.2 United Kingdom Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.3.2 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.3.4 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.1.1 Australia Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.1.2 Australia Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.2 China Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.2.1 China Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.2.2 China Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.3 India Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.3.1 India Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.3.2 India Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.4 Japan Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.4.1 Japan Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.4.2 Japan Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.3.5.5 South Korea Gastrointestinal Stromal Tumors Therapeutics Market
9.3.5.5.1 South Korea Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.3.5.5.2 South Korea Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.4.2 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.4.4 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.1.1 South Africa Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.1.2 South Africa Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4.5.2 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.2.1 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.2.2 Saudi Arabia Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.4.5.3 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market
9.4.5.3.1 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.4.5.3.2 U.A.E Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Overview
9.5.2 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Route Of Administration
9.5.4 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Gastrointestinal Stromal Tumors Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Gastrointestinal Stromal Tumors Therapeutics Market
9.5.5.1.1 Brazil Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.5.5.1.2 Brazil Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
9.5.5.2 Argentina Gastrointestinal Stromal Tumors Therapeutics Market
9.5.5.2.1 Argentina Gastrointestinal Stromal Tumors Therapeutics Market by Route Of Administration
9.5.5.2.2 Argentina Gastrointestinal Stromal Tumors Therapeutics Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GASTROINTESTINAL STROMAL TUMORS THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. AROG PHARMACEUTICALS, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BOSTON BIOMEDICAL
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. CELLDEX THERAPEUTICS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. F. HOFFMANN-LA ROCHE LTD
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IMMUNICUM AB.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NATCO PHARMA LIMITED
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. NOVARTIS AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. PFIZER INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. AROG Pharmaceuticals, INC.
2. Bayer AG
3. Boston Biomedical
4. Celldex Therapeutics
5. F. Hoffmann-La Roche Ltd
6. Immunicum AB.
7. NATCO Pharma Limited
8. Novartis AG
9. Pfizer Inc.
10. Sun Pharmaceutical Industries Ltd.